Canaccord Genuity Maintains a 'Buy' on Edwards Lifesciences (EW); Q4 Raises Questions; We Think Buying On Weakness Is The Answer
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $90.21 --0%
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 25
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 25
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $90.00.
Analyst, Jason R. Mills, said, "Q4 results and CMS’ proposed TAVI NCD will test investors’ conviction. EW’s business (and stock) will go as TAVI goes, given its impact on all aspects of the business – i.e. total revenue, GM and operating leverage. So, to buy this stock today on weakness, we believe investors must get comfortable with four primary TAVI-related issues: 1) FDA approval for Cohort A; 2) read-through from the proposed NCD; 3) potential for US SAVR turn around; and 4) OUS TAVI growth profile."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $80.67 yesterday.
Analyst, Jason R. Mills, said, "Q4 results and CMS’ proposed TAVI NCD will test investors’ conviction. EW’s business (and stock) will go as TAVI goes, given its impact on all aspects of the business – i.e. total revenue, GM and operating leverage. So, to buy this stock today on weakness, we believe investors must get comfortable with four primary TAVI-related issues: 1) FDA approval for Cohort A; 2) read-through from the proposed NCD; 3) potential for US SAVR turn around; and 4) OUS TAVI growth profile."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $80.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ResMed (RMD) PT Raised to $267 at KeyBanc Following Last Week's NDR
- Compass Point Upgrades MidCap Financial Investment Corp (MFIC) to Buy
- Cantor Fitzgerald Starts Braveheart Bio (BRVE) at Overweight
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
